Shots: CEPI’s total investment in Clover’s S-Trimer vaccine candidate will be up to $328 M, including $69.5M previously announced have funded preclinical studies and P-l study, preparations for the global pivotal P-ll/lll efficacy study, and initial manufacturing scale-up activities The expanded collaboration will provide $258.5M for a global pivotal P-ll/lll efficacy clinical trial which is […]Read More
Shots: The $1B support is for the development, production and delivery of the vaccine with its initiation in H2’20 including a P-III trial with 30,000 participants and a pediatric trial.AZ has initiated to provide wider access to University of Oxford’s vaccine and concluded to provide 400M doses has secured total manufacturing capacity for 1B doses […]Read More
Shots: The collaboration follows the existing partnership b/w J&J and BARDA while the company expects to initiate the clinical studies of selected vaccine candidates by Sept’2020 with the anticipated first batch of COVID-19 vaccine to be available for EUA in early 2021 Under the new agreement, J&J and BARDA to invest ~1B in research, development […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
